Risk Perception in Multiple Sclerosis

Status Completed

Clinical Trial Summary

This study was a retrospective, non-interventional, cross-sectional, multi-cohort study of patients clinically diagnosed with RMS (RRMS and SPMS). Patients were classified according to the immediate previous treatment in two groups, those who were prescribed with high efficacy treatments (HETs) and those who were prescribed with non-high efficacy treatments (non-HETs). HET include alemtuzumab, ofatumumab, ocrelizumab, natalizumab, cladribine, fingolimod and ozanimod; and non-HETs include molecules classified as with moderate or modest efficacy such as: interferons, glatiramer acetate, dimethyl fumarate and teriflunomide.

Clinical Trial Description

The study cohort consisted of RMS patients identified in the Adelphi Real World MS DSP, which was current up until the Q2/2021. The study was using waves VI-IX of the Adelphi DSP dataset. Study period: Q1 2017 - Q1 & Q2 2021 (waves VI-IX of Adelphi DSP dataset). Identification period: Q1 2017 - Q1 & Q2 2021 (waves VI-IX of Adelphi DSP dataset). Index date: defined as the dates when the surveys were carried out (Q1 2017 - Q1 & Q2 2021). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05528666
Study type	Observational
Source	Novartis
Contact
Status	Completed
Phase
Start date	September 9, 2021
Completion date	September 17, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03608527` - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis	N/A
Completed	`NCT02486640` - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed	`NCT01324232` - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis	Phase 2
Not yet recruiting	`NCT06020937` - Olfactory and Trigeminal Functions in Patients With Multiple Sclerosis: Case-control Study
Completed	`NCT04546698` - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting	`NCT04380220` - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed	`NCT02835677` - Integrating Caregiver Support Into MS Care	N/A
Completed	`NCT03686826` - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting	`NCT06021561` - Orofacial Pain in Multiple Sclerosis
Completed	`NCT03653585` - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting	`NCT04798651` - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis	N/A
Recruiting	`NCT05054140` - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis	Phase 2
Completed	`NCT05447143` - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis	N/A
Completed	`NCT04147052` - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis	N/A
Completed	`NCT03591809` - Combined Exercise Training in Patients With Multiple Sclerosis	N/A
Completed	`NCT03594357` - Cognitive Functions in Patients With Multiple Sclerosis
Completed	`NCT03269175` - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies	Phase 4
Completed	`NCT02845635` - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
Completed	`NCT02232061` - Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks	Phase 4
Terminated	`NCT04990219` - A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis	Phase 1